Bg pattern

RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Ruconest 2100 units powder and solvent for solution for injection

conestat alfa

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Ruconest and what is it used for
  2. What you need to know before you use Ruconest
  3. How to use Ruconest
  4. Possible side effects
  5. Storage of Ruconest
  6. Contents of the pack and other information

1. What is Ruconest and what is it used for

Ruconest contains conestat alfa as the active substance. Conestat alfa is a recombinant (non-blood-derived) form of human C1 inhibitor (rhC1-INH).

Ruconest should be used by adults, adolescents, and children (from 2 years of age) with a rare hereditary blood disorder called hereditary angioedema (HAE). These patients have a deficiency of the C1 inhibitor protein in their blood, which can cause repeated episodes of swelling, abdominal pain, difficulty breathing, and other symptoms.

Administration of Ruconest resolves the C1 inhibitor deficiency and allows a reduction of the symptoms of acute HAE attacks.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Ruconest

Do not use Ruconest:

  • If you are or are considered allergic to rabbits
  • If you are allergic to conestat alfa or any of the other components of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor before starting to use Ruconest.

If you experience allergic reactions, such as hives, rash, itching, dizziness, wheezing, difficulty breathing, or swelling of the tongue after administration of Ruconest, seek emergency medical assistance to urgently treat the symptoms of the allergic reaction.

Children and adolescents

Do not administer this medicine to children under 2 years of age. Ruconest has not been studied in children under 5 years of age. Your doctor will determine if treatment with Ruconest is suitable for your child. Additional monitoring of your child is required to detect symptoms of allergic reactions during and after administration.

Using Ruconest with other medicines

Tell your doctor if you are using, have recently used, or might use any other medicines.

If you receive tissue plasminogen activator as acute treatment for the prevention of blood clots (anticoagulant treatment), you should not use Ruconest at the same time.

Pregnancy and breastfeeding

Ruconest should not be administered during pregnancy or breastfeeding.

If you plan to become pregnant, consult your doctor before using Ruconest.

Driving and using machines

Do not drive or operate machines if you feel dizzy or have a headache after using Ruconest.

Ruconest contains sodium (19.5 mg per vial)

Patients on low-sodium diets should be aware that this medicine contains 19.5 mg of sodium per vial.

3. How to use Ruconest

Treatment with Ruconest will be initiated by a doctor specialized in the diagnosis and treatment of hereditary angioedema.

Ruconest should be administered by a healthcare professional until you or your caregiver have received the necessary training and are able to administer Ruconest.

Always use this medicine exactly as described in this leaflet or as directed by your doctor or nurse. Consult your doctor or nurse if you are unsure.

Ruconest is administered into a vein over approximately 5 minutes. Your dose will be based on your body weight.

Most of the time, one dose is sufficient. An additional dose may be administered if your symptoms do not improve after 120 minutes (for adults and adolescents) or 60 minutes (for children). No more than two doses, calculated according to step 7, should be administered within a 24-hour period.

You or your caregiver can inject Ruconest only after receiving adequate instructions and necessary training from your doctor or nurse.

Instructions for use

Do not mix or administer Ruconest with other medicines or solutions. The following describes how to prepare and administer the Ruconest solution.

Before you start

  • Make sure the packaging is intact and contains all the components specified in section 6 of this leaflet.
  • In addition to the packaging, you will need:
    • A tourniquet
    • Adhesive tape to secure the needle
  • Inspect the vials and other components.
    • All vials must be sealed with a plastic cap and an aluminum stopper without visible damage, such as cracks in the glass.
    • Check the expiration date. Do not use any component of the kit after the expiration date indicated on the large outer packaging.

In a single box, the different components may have different expiration dates. The expiration date of the outer packaging reflects the expiration date of the component with the shorter validity period.

  • Wait until the required number of powder and solvent vials reach room temperature.

Mathematical formula that calculates volume with body weight in kilograms and initial dose in milligrams

Preparation of the solution

Step 1:Cleaning and other requirements

  • Wash your hands thoroughly.
  • Place the required powder and solvent vials on a flat and clean surface.
    • Body weight of 42 kg or less: 1 vial of powder and 1 vial of solvent
    • Body weight over 42 kg: 2 vials of powder and 2 vials of solvent
  • Place the vial adapters on the work surface. Do not remove the packaging from the adapters.
    • 2 adapters for 1 vial of powder and 1 vial of solvent
    • 4 adapters for 2 vials of powder and 2 vials of solvent
  • Place the syringes on the work surface. Do not remove the packaging from the syringes.
    • 1 syringe for 1 vial of powder and 1 vial of solvent
    • 2 syringes for 2 vials of powder and 2 vials of solvent

Step 2:Disinfection of vial stoppers

  • Remove the plastic pressure cap from the powder and solvent vials.
  • Use an alcohol swab to disinfect all vial stoppers and wait at least 30 seconds until the stoppers are dry.

Hand placing a cotton swab soaked with liquid over the injection site on the skin, gently pressing with the fingers

  • After disinfection, do not touch the stoppers with your hands or any object.

Step 3:Assembly of adapters on vials

  • Hold a packaged adapter with one hand and remove the cap. The adapter should remain in its plastic packaging.
  • Place the adapter on a powder vial and pierce the stopper until it is secured to the neck of the vial.

Vial cap with arrows indicating rotation to open and push to close, showing the sealing mechanism

  • Leave the adapter packaging on until you connect the syringe according to steps 4 and 5.
  • Repeat the above steps to assemble an adapter on the solvent vial. All adapters supplied in the packaging are identical.
  • If you need to use a second powder and solvent vial, repeat the above steps.

Step 4:Withdrawal of solvent

  • Remove a sterile syringe from its packaging.
  • Remove the adapter packaging from the solvent vial.

Cylindrical adapter with arrow indicating direction of engagement over base with vertical grooves

  • Hold the adapter with one hand. With the other hand, connect the syringe and turn it to the left until it stops to secure it.

Hand holding an auto-injector with the needle exposed and a curved arrow indicating the direction of insertion

  • Invert the solvent vial completely along with the adapter and syringe. While keeping it in a vertical position, slowly inject 14 ml of solvent.

If bubbles form, minimize them as much as possible. To do this, give a light tap on the syringe and apply gentle pressure by pushing the plunger in the syringe. Continue filling the syringe until you reach the 14 ml of solvent.

Two pre-filled syringes with transparent liquid showing measurement marks and a plunger with an arrow indicating the direction of pressure

  • To disconnect the syringe from the adapter, turn it to the left.

Needle connected to a cylinder with measurement marks and a removable transparent protector, arrow indicates rotation

  • Leave the remaining solvent in the vial and discard the vial.
  • Place the syringe on the work surface and avoid touching the surface or any other object with the tip of the syringe.

Step 5:Addition of solvent to powder and dissolution

  • Remove the adapter packaging from the powder vial.
  • Take the syringe with solvent that you prepared in step 4.
  • Hold the adapter with the other hand and connect the syringe. To secure the syringe, turn it to the right until it stops.
  • Slowly press the solvent with a single movement to introduce it into the powder vial and minimize foam formation.

Vial with stopper and adapter showing connection arrows and preparation for injection

  • Leave the syringe in the adapter and carefully turn the vial for about half a minute. Do not shake it.

After turning, leave the vial on the surface for several minutes until the solution is clear. If there is undissolved powder, repeat the procedure.

Glass bottle with aerosol cap and hand turning the nozzle, indicating direction with curved arrows

  • Repeat steps 4 and 5 if you need to prepare a second solution.

Step 6:Checking prepared solutions

  • Check if the powder from the vials has dissolved completely and if the plunger is at the bottom of the syringe.
  • Once the powder is dissolved, the solution should be clear and colorless.
  • Do not use the prepared solution if it is cloudy, contains particles, or has changed color. Inform the healthcare professional in this case. A small amount of foam formation is acceptable.

Needle connected to an administration device with a pressed plunger and a dotted line indicating the direction of injection

Step 7:Withdrawal of prepared solution

  • Calculate the milliliters of prepared solution to be injected.

Body weight

Milliliters of prepared solution to be injected

Less than 84 kg

Body weight in kg divided by three

84 kg and over

28 ml

  • Inject the volume of prepared solution while keeping the syringe in a vertical position. If you have prepared:
    • one vial with solution, withdraw the calculated volume
    • two vials and your body weight is less than 84 kg, withdraw a similar amount:
    • 14 ml from the first vial
    • from the second vial, the difference between the calculated volume and the 14 ml from the first vial
    • two vials and your body weight is 84 kg or more, withdraw 14 ml from each vial in each syringe

If bubbles form, minimize them as much as possible. To do this, give a light tap on the syringe and apply gentle pressure by pushing the plunger in the syringe. Continue filling the syringe until you reach the required volume.

Syringe with a spiral mixing device connected to its lower end, arrow indicates direction of use

  • Never exceed the volume of 14 ml per syringe.
  • To release the syringe, turn it to the left and discard the vials along with the adapter.
  • Place the syringe on the work surface and avoid touching the surface or any other object with the tip of the syringe.

Step 8:Checking prepared syringes

  • Re-check if the volume of the syringes prepared in step 7 is correct.

Administration into a vein

It is very important that the prepared solution is injected directly into a vein and not into an artery or the surrounding tissue.

Inject the Ruconest solution immediately after preparation, preferably while seated.

Step 9:Required components

  • Check if all necessary components are on the work surface:

- 1 or 2 syringes with the prepared solution

- 1 infusion set with a 25 G needle

- 1 alcohol swab

- 1 non-woven sterile gauze

- 1 self-adhesive dressing

- 1 tourniquet

- 1 adhesive tape to secure the needle

Step 10:Preparation of the infusion set

  • Remove the screw cap from the end of the infusion set. This is the end without the needle.
  • Hold this end with one hand, connect the syringe tip, and secure it by turning it to the right until it stops.
  • Hold the syringe with the tip upwards. Gently press the syringe plunger to carefully fill the infusion set with the prepared solution.

Hand holding a syringe with a flexible catheter inserted into the skin, arrow indicating direction of insertion

  • Check that there is no air in the syringe, infusion tube, or needle.

Step 11:Preparation of the injection site

  • Place the tourniquet over the injection site, preferably in the middle of the upper arm. Tighten to compress the vein. You can achieve this effect by clenching your fist.
  • Palpate the suitable vein with the other hand.
  • Disinfect the injection site well with an alcohol swab and let the skin dry.

Hand applying an adhesive patch on the upper arm with curved arrows indicating the direction of application

Step 12:Administration of the prepared solution

  • Remove the needle cover.
  • Insert the infusion set needle carefully, at the most shallow angle possible, into the vein.

Arm with a venous infusion device connected to an intravenous line with an arrow indicating the flow of liquid

  • Secure the needle with the adhesive tape, approximately 7 cm long, over the wings of the needle.
  • Gently and slightly pull back the syringe plunger until you see blood enter the tube to ensure the needle is in the vein.
  • Release the tourniquet.
  • If there is no blood in the tube, remove the needle, repeat all steps from step 11, and reinsert the needle.
  • If there is blood, carefully inject the solution into the vein, as shown in the image. Inject over approximately 5 minutes.

Arm with a tourniquet and needle inserted for intravenous injection with syringe and arrow indicating direction

  • If you have prepared two syringes:

- Fold the tube near the connector of the infusion set to avoid flow inversion

- Unscrew the empty syringe from the infusion set and immediately replace it with the second syringe.

Hand holding an auto-injector with the needle exposed, ready to inject into the skin fold

- Unfold the tube and carefully inject this solution in a similar way to the first syringe.

Step 13:After administration

  • Carefully remove the adhesive tape that secures the needle and remove the needle from the vein.
  • Immediately after removing the needle, press the sterile gauze over the injection site for a few minutes to reduce bleeding.

Hand holding an auto-injector with an arrow indicating pressure on the button and arm showing the injection site

  • Then, place the self-adhesive dressing over the injection site.
  • Fold the yellow protective cap over the needle.
  • Safely discard the used infusion set with the needle, unused solution, syringe, and empty vial in an appropriate waste container, as these materials can cause injury if not disposed of properly. Do not reuse the equipment.

Step 14:Documentation of administration

Record the following (for example, in your diary):

  • Date and time of administration
  • Batch number printed on the label of the powder vial

If you use more Ruconest than you should

Contact your doctor or the nearest hospital.

If you have any further questions on the use of this medicine, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

If your symptoms worsen and/or you present with a rash, tingling, difficulty breathing, or swelling of the face or tongue, consult your doctor immediately. These symptoms may indicate that you have developed an allergy to Ruconest.

During treatment with Ruconest, some side effects may appear:

Frequent: may affect up to 1 in 10 people

  • Nausea

Infrequent: may affect up to 1 in 100 people

  • Abdominal pain, diarrhea
  • Sensation of tingling, pinching, or numbness of the mouth
  • Headache, dizziness
  • Decreased sense of touch or sensitivity in the skin or extremities
  • Throat irritation
  • Urticaria (hives)
  • Swelling of the ears or the area around the ears

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect that does not appear in this prospectus. You can also report it directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Ruconest

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging and on the label of the vial after EXP. The expiration date is the last day of the month indicated.

Do not store at a temperature above 25°C.

Keep the powder vial in the vial box to protect it from light.

Before administering Ruconest, it must be dissolved in the solvent included in the packaging (see section 3). Once reconstituted, the product must be used immediately.

Do not use this medicine if, after dissolution, you observe that the solution contains particles or if the solution is discolored. The formation of foam is acceptable in small quantities.

6. Package Contents and Additional Information

Composition of Ruconest

Powder vial:

  • The active ingredient is conestat alfa. One powder vial contains 2100 units (U) of conestat alfa. This is equivalent to 2100 units per 14 ml after reconstitution, or a concentration of 150 units/ml.
  • The other components are sucrose, sodium citrate (E331), and citric acid.

Solvent vial:

  • The solvent ingredient is water for injectable preparations.

Appearance of the Product and Package Contents

Ruconest is presented in a single glass vial containing a white to off-white powder for injectable solution, along with a glass vial with a clear, colorless solvent to dissolve the powder. After dissolving the powder in water for injectable preparations, the solution is clear and colorless.

Ruconest is supplied as a kit in a box that contains:

  • 1 vial of 2100 U of powder
  • 1 vial of 20 ml of solvent
  • 2 vial adapters
  • 1 syringe
  • 1 infusion set with a 35 cm tube and a 25 G needle
  • 2 alcohol swabs
  • 1 non-woven sterile gauze
  • 1 self-adhesive bandage

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Pharming Group N.V.

Darwinweg 24

2333 CR Leiden

Netherlands

Manufacturer:

Pharming Technologies B.V.

Darwinweg 24

2333 CR Leiden

Netherlands

Date of the Last Revision of this Prospectus:

Detailed information about this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu/.

------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

DOSAGE AND ADMINISTRATION

Dosage

Body weight up to 84 kg

  • An intravenous injection of 50 U/kg of body weight.

Body weight of 84 kg or more

  • An intravenous injection of 4200 U (two vials).

In most cases, a single injection of Ruconest is sufficient for the treatment of an acute angioedema crisis.

If the clinical response is insufficient, a second dose (50 U/kg of body weight up to 4200 U) may be administered.

No more than two doses can be administered within a 24-hour period.

Dose Calculation

Determine the patient's body weight.

Body weight up to 84 kg

  • In patients weighing up to 84 kg, the administration volume required will be calculated using the following formula:

Volume to be Administered (ml)

=

Body Weight (kg) x 50 (U/kg)

150 (U/ml)

=

Body Weight (kg)

3

Body weight of 84 kg or more

  • In patients weighing 84 kg or more, the administration volume required is 28 ml, equivalent to 4200 U (2 vials).

Reconstitute each vialwith 14 ml of water for injectable preparations (see Reconstitution section below).

The reconstituted solution in each vial contains 2100 U of conestat alfa at 150 U/ml.

The required volume of the reconstituted solution should be administered by slow intravenous injection over approximately 5 minutes.

SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

Preparation and Handling

Each vial of Ruconest is for single use.

Ruconest should be administered intravenously after reconstitution with water for injectable preparations. Aseptic technique should be used for reconstitution, combination, and mixing of solutions.

Reconstitution

  1. Each vial of Ruconest (2100 U) should be reconstituted with 14 ml of water for injectable preparations.
  2. Disinfect the rubber stoppers of the powder and solvent vials, and place a vial adapter on each vial of solvent and powder to connect it to the vial neck.
  3. Connect the syringe to the adapter of the solvent vial and turn it to the right until it is connected. To release the syringe from the adapter, turn it to the left and discard the vial along with the adapter.
  4. Connect the syringe with solvent to the adapter of the powder vial and turn it to the right until it is connected. The solvent should be added slowly to avoid strong impact on the powder and mixed gently to minimize foam formation in the solution. Leave the syringe in the adapter. Repeat steps 3 and 4 if you need to prepare a second solution (this requires a second package).
  5. The reconstituted solution contains 150 U/ml of conestat alfa and is a clear, colorless solution. The reconstituted solution in each vial should be examined for particles and color changes. Do not use a solution that presents particles or color changes. The formation of small amounts of foam is acceptable. This medicine should be used immediately.

Administration

  1. Inject the required volume of the prepared solution. Do not exceed 14 ml per syringe. To release the syringe, turn it to the right and discard the vial along with the adapter.
  2. Connect the infusion set to the syringe and turn it to the right to lock it. Hold the syringe with the tip upwards and gently press the plunger to fill the infusion set with solution.
  3. Disinfect the injection site with an alcohol swab. Remove the needle cover from the infusion set and carefully insert the needle into the vein.
  4. Make sure to release the tourniquet. Inject the solution into the vein carefully (over approximately 5 minutes).
  5. If preparing two syringes, fold the tube to avoid flow inversion, unscrew the empty syringe from the infusion set (to the left) and immediately replace it with the second syringe. Inject the solution from the second syringe carefully.

Disposal

Safely dispose of the used infusion set with the needle, unused solution, syringe, and empty vial in an appropriate medical waste container, as these materials can cause injury if not disposed of correctly. Do not reuse the equipment.

Online doctors for RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Discuss questions about RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
The active ingredient in RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION is conestat alfa. This information helps identify medicines with the same composition but different brand names.
Who manufactures RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION is manufactured by Pharming Group N.V.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (conestat alfa) include RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION, ANDEMBRY 200 mg INJECTABLE SOLUTION IN PRE-FILLED PEN, BERINERT 1500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media